1. 1. Le Loët X, Nordström D, Rodriguez M, et al. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial. J Rheumatol 2008;35:1538-44.
2. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial;Nuki;Arthritis Rheum,2002
3. 3. Di Domizio J, Castagna J, Algros MP, et al. Baricitinib-induced paradoxical psoriasis. J Eur Acad Dermatol Venereol 2020;34e391-3.
4. Risankizumab-induced paradoxical pustular psoriasis;McFeely;Clin Exp Dermatol,2022
5. New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra;González-López;Br J Dermatol,2008